semaglutide cardiac protection and the Heart: clinical insights from the SELECT Trial Insights into semaglutide cardiovascular research:

There are many identifiable symptoms of low blood sugar, but the only way to know if you have low blood sugar is by taking a blood glucose test

By product type, the GLP-1 receptor agonists segment held the largest market share in 2025 and is expected to grow at the fastest CAGR during the projection period

In addition, we discuss the increase in the endogenous secretion of this hormone through various stimuli (e.g., carbohydrates, proteins, gut microbiota, bacteria-derived molecules, bile acids, lipids, fatty acids, polyphenols, etc.) or by the increase of GLP-1-producing cells, i.e., L-cells, which can be an appropriate approach for the management of diabetes

The outcome of the case, whether it is a settlement or a trial verdict, applies collectively to all class members